Experiments were done to assess the compatibility of nateglinide with selected excipients in the development of immediate release tablets of nateglinide by thermal and isothermal stress testing (IST) techniques. To evaluate the drug-excipient compatibility, different techniques such as differential scanning calorimetric (DSC) study, infra-red (IR) spectrophotometric study and isothermal stress testing were adopted. The results of DSC study showed that magnesium stearate exhibited some interaction with nateglinide. However, the results of IR, and IST studies showed that all the excipients used in the formula were compatible with nateglinide. Optimized formulations developed using the compatible excipients were found to be stable over 3 months of accelerated stability studies (40 ± 2°C and 75 ± 5% RH). Overall, compatibility of excipients with nateglinide was successfully evaluated using a combination of thermal and IST methods and the formulations developed using the compatible excipients were found to be stable.
A single intraperitoneal injection of lead acetate (200 mg/kg body weight) increased the lipid peroxidation potential (LPP) measured as thiobarbituric acid-reactive substance (TBA-RS) in different tissues of Swiss mice. All the tissues taken for experimentation, generated significantly higher amount of TBA-RS in lead-treated mice when compared with the respective control value. However, none of the tissues could correspond to the control value after the lapse of four weeks posttreatment. Possibilities of differential responsiveness of tissues to generate lipid peroxides in leadtreated mice have been discussed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.